Effects of edaravone on early postoperative cognitive function in elderly patients undergoing hip joint replacement surgery
Phase 1
Recruiting
- Conditions
- Postoperative cognitive dysfunction
- Registration Number
- ITMCTR1900002523
- Lead Sponsor
- Shanghai Pudong Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients aged 60 years and over; received hip joint replacement surgery; informed consent; ASA I or II.
Exclusion Criteria
History of psychiatric disorders, cerebrovascular diseases and diabetes; long term use of nervous and mental system drugs (such as sedative hypnotics and antidepressants); history of alcohol abuse; severe impairment on speaking, hearing and vision that difficult to communicate; MMSE score < 23 one day before surgery.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does edaravone target to improve postoperative cognitive dysfunction in elderly patients?
How does edaravone compare to standard-of-care treatments for postoperative cognitive dysfunction in geriatric hip surgery patients?
Are there specific biomarkers that predict response to edaravone in preventing postoperative cognitive decline?
What are the potential adverse events associated with edaravone administration in elderly surgical populations?
What other antioxidants or neuroprotective agents are being studied for postoperative cognitive dysfunction alongside edaravone?